Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


South Korean Ministry of Health's Lee Hae-hee On Partnership With AstraZeneca To Bolster Domestic Firms' Global Aspirations: An Interview With PharmAsia News.

This article was originally published in PharmAsia News

Executive Summary

SEOUL - AstraZeneca Plc. signed a memorandum of understanding with South Korea's Ministry of Health and Welfare April 4 to commit to an R&D investment of KRW 80 billion ($73.48 million) in Korea through the next five years. The company also agreed to provide training and information exchanges to Korea's pharma industry, which is looking for inroads into foreign markets. The MOU is a follow-up to an MOU signed between the two parties in 2006. Lee Hae-hee, healthcare R&D assistant director at South Korea's Ministry of Health and Welfare, discussed the deal - announced in early April - with PharmAsia News on the sidelines of Medical Korea.

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts